Clinical Trials Sponsored by Salwa Elgendy

Total 87 results

Beijing Boren Hospital
Nanjing Legend Biotech Co.

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

T-cell Leukemia | T Cell Lymphoma

China
Universidad Nacional de Salta
Albert B. Sabin Vaccine Institute; Fundacion Mundo Sano

Unknown

Management of Soil-transmitted Helminthiasis and Strongyloidiasis

Helminthiasis | Strongyloides Stercoralis Infection

Argentina
ClinAmygate
Fayoum University Hospital; Misr University for Science and Technology; Al Safwa...

Completed

Triclosan-antibacterial Sutures Impact on the Incidence of Surgical Site Infection in Laparoscopic Surgeries.

Laparoscopic Surgery | Surgical Wound | Surgical Site Infection

Egypt
Nanjing Legend Biotech Co.
Janssen Research & Development, LLC

Recruiting

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1)

Multiple Myeloma

China
First Affiliated Hospital Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma

Gastric Cancer | Pancreatic Ductal Adenocarcinoma

China
yasmin gamal el gendy

Completed

Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students

Iron Deficiency Anemia

Egypt
Sanwa BioTech Limited
Chinese University of Hong Kong; Prince of Wales Hospital, Shatin, Hong Kong

Not yet recruiting

Influenza A+B Test Kit Performance Study

Influenza Type B | Influenza Type A

Hong Kong
Weijun Fu
Nanjing Legend Biotech Co.

Recruiting

BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Weijun Fu
Nanjing Legend Biotech Co.

Active, not recruiting

A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...
Nanjing Legend Biotech Co.

Terminated

CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Universidad Nacional de Salta
Fundacion Mundo Sano; CIVETAN-Tandil, UNCPBA; Natural History Museum, London, UK

Completed

Urine Albendazole Levels for Coverage Assessment

Helminthiasis

Argentina
Tianjin Medical University Cancer Institute and...
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | B-Cell Non-Hodgkin Lymphoma-Refractory

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Qiu Lugui
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Not yet recruiting

Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...
Nanjing Legend Biotech Co.

Active, not recruiting

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

Acute Myeloid Leukemia | Acute Leukemia | Acute Leukemia in Relapse | Relapsed or Refractory Acute Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
Evgeny Shkolnik, MD
Vilnius University; Medispec

Completed

Efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy in Patients With Stable Angina Pectoris

Stable Angina Pectoris

Lithuania, Russian Federation
Salma Sabbour
Bristol-Myers Squibb; Rutgers Cancer Institute of New Jersey; BeyondSpring Pharmaceuticals...

Active, not recruiting

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Lung Cancer | SCLC

United States
Shanghai East Hospital
Anhui Provincial Hospital; Nanjing Legend Biotech Co.; East Clinical Center of...

Terminated

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer

Epithelial Ovarian Cancer

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co.,Ltd.

Terminated

A Study on the Collection of Peripheral Blood Mononuclear Cells From Healthy Volunteers for the Development of Allogeneic Cellular Immunotherapy Products

Collection of Peripheral Blood Mononuclear Cells by Means of Apheresis

China
ClinAmygate
Misr University for Science and Technology; Al Safwa Hospital; Al Zohour Hospital and other collaborators

Recruiting

Triclosan-antibacterial Sutures Efficacy on the Incidence of Surgical Site Infection in Clean-contaminated Wounds

Surgical Wound | Surgical Wound Infection | Surgical Site Infection

Egypt
Jun Zhu
Nanjing Legend Biotech Co.

Recruiting

Collection of PBMCs From Healthy Subjects for the Development of Cellular Immunotherapy Product

Healthy Subject

China
Alejandro Krolewiecki
Brock University; Universidad Nacional del Centro de la Provincia de Buenos... and other collaborators

Completed

Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients (HI4T)

Helminthiasis | Trichuris Infection

Argentina, Honduras
jianming xu
Nanjing Legend Biotech Co.

Recruiting

GPC3-targeting LCAR-H93T Cell in Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Laboratorio Elea Phoenix S.A.
Universidad Nacional de Salta; Centro de Investigación Veterinaria Tandil CIVETAN and other collaborators

Completed

Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19

COVID-19 Drug Treatment

Argentina
Nanjing Legend Biotech Co.
Ruijin Hospital; Second Affiliated Hospital of Xi'an Jiaotong University; Shanghai... and other collaborators

Active, not recruiting

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)

Refractory or Relapsed Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co.,Ltd.; The First Affiliated Hospital of USTC...

Terminated

Study of LUCAR-20S in Patients With R/R NHL

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China
University of Jyvaskyla
University of Helsinki; University of Eastern Finland; VTT Technical Research... and other collaborators

Completed

Study of Effectiveness of Different Lifestyle Interventions for Health and Wellbeing

Overweight | Psychological Stress | Metabolic Syndrome Risk Factors

Finland
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west...

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

China
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Dr. Bonaventura Clotet Sala; Dr. Josep Mª LLibre Codina; Dr. Boris Revollo Barriga and other collaborators

Completed

Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures

COVID-19 (SARS-CoV-2)

Spain
Pediatric Clinical Research Platform
Geneva Emergency Medical Services, Geneva, Switzerland; Lausanne Emergency... and other collaborators

Completed

Reducing Prehospital Medication Errors & Time to Drug Delivery by EMS During Simulated Pediatric CPR

Emergency Medical Services | Pediatrics | Resuscitation | Cardiopulmonary Arrest | Medication Errors

Switzerland
Cardiovascular Center Frankfurt
Sheba Medical Center; Kerstin Piayda, CardioVascular Center Frankfurt, Frankfurt... and other collaborators

Active, not recruiting

Therapy Strategies After LAA Occluder Device Embolization (LAAODE)

Risk Factors | Left Atrial Appendage Occluder | Device Embolisation | Therapy Strategies

Germany

Clinical Trials Sponsored by Salwa Elgendy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations